Biotech Archives - Page 126 of 795

2 minute read

Aclarion Announces Updated Product Release That Expands MRI Scanner Access For Nociscan Solution

January 17, 9:23 AM

Nociscan is the first augmented intelligence platform to measure pain biomarkers in the lumbar spineThis new product release expands accessibility of Nociscan on the worldwide MR marketBuilds on preexisting

ACON

4 minute read

Perspective Therapeutics, Inc. Commences Recruitment For Second Dose Escalation Cohorts In Clinical Studies Of Two Lead Programs

By Benzinga Newsdesk

January 17, 9:19 AM

Perspective Therapeutics, Inc. (NYSE:CATX), today announced that it began patient recruitment for the second dosing cohorts (Cohort 2) in clinical studies for both of its lead product candidates, [212Pb]VMT-α-NET and

CATX

1 minute read

Daré Bioscience Announces Grant From The Bill & Melinda Gates Foundation Of $750,000 To Fund Activities Related To Bacteria-Based Live Biotherapeutic Product Development

By Benzinga Newsdesk

January 17, 9:18 AM

Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, today announced it has received a grant from the Bill & Melinda Gates Foundation (the foundation) of $750,000 to fund activities related to

DARE

1 minute read

GSK Cuts More Stake In Its Spun-Off Consumer-Healthcare Business Haleon, Raises Over £900M

By Vandana Singh

January 17, 9:14 AM

GSK sells 300M shares in Haleon at £326/share, raising £978M. GSK to retain 4.2% stake.

GSK

2 minute read

Paragon 28 Announces First Cases and Limited Market Release Of The Bun-Yo-Matic – A Next Generation Clamp And Cut Guide System For Lapidus Bunion Procedures

By Benzinga Newsdesk

January 17, 9:04 AM

Paragon 28, Inc. (NYSE:FNA), is excited to announce the limited market release of its Bun-Yo-Matic™ Lapidus Clamp System and completion of the first surgical cases in Orange County, California and Seattle,

FNA

2 minute read

FDA
News

Gene Therapy For Beta-Thalassemia: CRISPR Therapeutics/Vertex’s Casgevy Secures FDA Nod Ahead of Schedule

By Vandana Singh

January 17, 8:15 AM

FDA approves CRISPR Therapeutics/Vertex's Casgevy a gene-edited cell therapy for transfusion-dependent beta-thalassemia. Vertex's swift launch strategy targets a network of treatment centers across the U.S.

BLUE

1 minute read

FDA
News

Incannex Received IRB Approval For RePOSA Phase 2/3 Clinical Trial Protocol To Assess IHL-42X Drug In Patients With Obstructive Sleep Apnea

By Charles Gross

January 17, 7:12 AM

Incannex Healthcare Inc. (NASDAQ:IXHL), (‘Incannex’ or the ‘Company’), a pharmaceutical company developing unique medicinal cannabinoid pharmacotherapies and psychedelic medicine

IXHL

2 minute read

Cholesterol Player NewAmsterdam Pharma’s Obicetrapib Is A Potential Blockbuster In Cardiovascular Market: Bullish Analyst Says

By Vandana Singh

January 16, 3:48 PM

Piper Sandler's coverage on NewAmsterdam Pharma and its clinical-stage therapy, Obicetrapib, a potent CETP inhibitor targeting cardiovascular health. With a unique mechanism, superior efficacy, and market potential, Piper gives an Overweight rating and a $37 price target.

NAMS

1 minute read

Why Is Dermatology Focused Aclaris Therapeutics Stock Trading Higher Today?

By Vandana Singh

January 16, 12:47 PM

Aclaris Therapeutics leadership changes and strategic review. Preliminary unaudited data as of Dec 31, 2023, reveals approximately $182M in cash, cash equivalents, and marketable securities. Aclaris reiterates business plans for ongoing programs.

ACRS